Boehringer Ingelheim China posts robust business performance in 2021

German multinational pharmaceutical company Boehringer Ingelheim has maintained strong growth in the Chinese market as all three major business units achieved outstanding performance last year to propel the company's overall rapid development in China, according to the company's annual result report for 2021 unveiled on Tuesday.

Felix Gutsche, president and CEO of Boehringer Ingelheim Greater China, said the huge potential of the Chinese market and people's demand for high-quality healthcare products and services represent the biggest opportunities for Boehringer Ingelheim in China, and the company will continue to deeply engage with the Chinese market.

It will work with all partners to advance all-round open innovation, contribute to the high-quality development of China's healthcare industry, and comprehensively improve the health of humans and animals, he said.

According to the annual result report, Human Pharma was still the main revenue contributor, helping the company retain a leading position among multinational pharma companies in China. Animal Health posted strong double-digit growth and continued to be the leader in swine vaccine and pet antiparasitics segments. Biopharma Contract Development and Manufacturing Organization (CDMO) business achieved robust annual growth of 56 percent.